These are molecules designed to mimic the action of native GLP-1, the incretin hormone your gut releases after eating
A 2025 review in Cell highlighted the benefit of GLP-1 therapies on anti-inflammatory mechanisms involved in cardiovascular, kidney and liver conditions, and disorders like obstructive sleep apnea
doi:10.3171/jns.2005.103.4.0760
However, compounded GLP-1s are not FDA-approved and, as a result, come with a level of risk
NCOA4, as a key receptor for ferritinophagy, can specifically bind to the conserved surface arginine residues of the ferritin heavy chain at its C-terminus, promoting iron release during autophagosome formation and autolysosome maturation (Liu et al., 2025)
We understand how discouraging that can be